Clinical Report: ORC6 Identifies a Malignant Epithelial State in OSCC

Overview

This study identifies ORC6 as a marker of a malignant epithelial state in oral squamous cell carcinoma (OSCC), associated with adverse clinicopathological features.

Background

Oral squamous cell carcinoma (OSCC) is a prevalent and aggressive cancer subtype. Understanding the biological heterogeneity and immune context of OSCC is crucial.

Data Highlights

No numerical data or trial data presented in the article.

Key Findings

• ORC6 is upregulated in OSCC tissues and cell lines, correlating with adverse clinicopathological features.
• High ORC6 expression is associated with poorer survival outcomes in OSCC patients.
• Single-cell analysis indicates ORC6 enrichment in malignant epithelial cells, marking a replication-active state.
• ORC6 expression inversely correlates with immune-related features, including cytolytic activity and antigen presentation.
• Knockdown of ORC6 in CAL27 cells reduces cell growth and enhances antigen-presentation-associated transcripts.

Clinical Implications

The findings indicate that ORC6 may be associated with aggressive OSCC phenotypes.

Conclusion

ORC6 is a marker of a malignant epithelial state in OSCC. Further studies are needed to explore its implications.

Related Resources & Content

1. Frontiers in Oncology, 2026 -- Oncogenic viruses and their role in oral cavity and oropharyngeal squamous cell carcinoma: a systematic review
2. Frontiers in Oncology, 2026 -- Molecular and microenvironmental drivers of malignant transformation from oral potentially malignant disorders to oral squamous cell carcinoma
3. The ASCO Post, 2019 -- Oral HPV DNA Persistence and Disease Progression in Oral Cavity and Oropharyngeal Squamous Cell Carcinoma
4. Frontiers in Immunology — HPV-specific innovations and controversies in therapeutic strategies for HPV-associated oropharyngeal carcinoma
5. NCCN Guidelines for Head and Neck Cancers
6. AJCC 8th Edition Staging of Oral Cavity Cancer: Radiologic Evaluation
7. Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up
8. Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141 - PubMed
9. Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer | New England Journal of Medicine
10. Uncovering immune checkpoint heterogeneity in oral squamous cell carcinoma using single cell RNA-sequencing data highlights three subgroups of patients with distinct immune phenotypes - ScienceDirect
11. Spatial transcriptomics reveals that metabolic characteristics define the tumor immunosuppression microenvironment via iCAF transformation in oral squamous cell carcinoma - PubMed
12. Tumor mutational burden predictability in head and neck squamous cell carcinoma patients treated with immunotherapy: systematic review and meta-analysis - PubMed
13. Multiple mechanisms for licensing human replication origins | Nature
14. Replication licensing regulated by a short linear motif within an intrinsically disordered region of origin recognition complex | Nature Communications